Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.51 |
| ▸ | CCR5 | P51681 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 3/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.43 |
| ▸ | KDR | P35968 | 6/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | TEK | Q02763 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5961522 | 0.92 | CCR2 (0.53) | CCR2CCR5BRAFNR3C1TRPV1 | |
| SCHEMBL5961427 | 0.90 | CCR2 (0.51) | CCR2CCR5BRAFNR3C1TRPV1 | |
| SCHEMBL5961472 | 0.90 | CCR2 (0.63) | CCR2CCR5BRAFNR3C1KDR | |
| SCHEMBL5961525 | 0.89 | CCR2 (0.54) | CCR2CCR5BRAFNR3C1KDR | |
| SCHEMBL5961478 | 0.86 | CCR2 (0.48) | CCR2CCR5SMN1; SMN2 | |
| SCHEMBL7137484 | 0.85 | SPR (0.43) | CCR2CCR5NR3C1SMN1; SMN2 | |
| SCHEMBL7074009 | 0.85 | NR3C1 (0.48) | CCR2CCR5NR3C1 | |
| SCHEMBL5961440 | 0.85 | TP53 (0.47) | CCR2CCR5NR3C1KDR | |
| SCHEMBL5961537 | 0.84 | CCR2 (0.45) | CCR2CCR5NR3C1TRPV1SMN1; SMN2 | |
| SCHEMBL5961517 | 0.84 | MCL1 (0.43) | CCR2CCR5NR3C1TRPV1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6670364-B2 | For example (1,3-dimethylpyrazolo(5,4-b)pyridin-5-yl)-N-(((4-fluorophenyl) amino)carbonyl)-carboxamide; useful in prevention or treatment of chronic or acute inflammatory or autoimmune diseases | TELIK, INC. | 2003-12-30 | — | — | US | claimed |
| US-20030096705-A1 | Antagonists of MCP-1 function and methods of use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2003-05-22 | — | — | US | claimed |
| US-6992086-B2 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-6670364-B2 | For example (1,3-dimethylpyrazolo(5,4-b)pyridin-5-yl)-N-(((4-fluorophenyl) amino)carbonyl)-carboxamide; useful in prevention or treatment of chronic or acute inflammatory or autoimmune diseases | TELIK, INC. | 2003-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096705-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | CCR2 1/4885CCR5 4/4885BRAF 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.